HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients.

Abstract
Seventy-eight patients with cancer experienced 88 episodes of fever while neutropenic and were randomly assigned to receive empiric antibiotic therapy with cefoperazone 2 g intravenously every 12 hours and mezlocillin 4 g intravenously every six hours or imipenem/cilastatin 500 mg intravenously over 30 to 60 minutes every six hours. Within 96 hours of starting antibiotic treatment, 24 patients (57 percent) treated with cefoperazone and mezlocillin and 34 patients (74 percent) receiving imipenem/cilastatin became afebrile. One half of the patients in each arm required changes in the antibiotic regimen because of side effects, persistent fever with a site suspicious for infection, resistant organisms, or breakthrough bacteremias. Forty patients (95 percent) receiving cefoperazone and mezlocillin and 43 patients (93 percent) receiving imipenem/cilastatin recovered from the neutropenic episode. Two patients in each regimen group died of their underlying disease. One patient in the imipenem/cilastatin arm died of Pseudomonas aeruginosa sepsis. Although the two regimens are comparable in efficacy, the incidence of side effects favored the cefoperazone and mezlocillin group. No seizures or bleeding were seen in either arm; however, 19 patients (41 percent) receiving imipenem/cilastatin required pretreatment antiemetic drugs for nausea.
AuthorsJ Mortimer, S Miller, D Black, K Kwok, W M Kirby
JournalThe American journal of medicine (Am J Med) Vol. 85 Issue 1A Pg. 17-20 (Jul 25 1988) ISSN: 0002-9343 [Print] United States
PMID3400679 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Bacterial Agents
  • Cyclopropanes
  • Drug Combinations
  • Thienamycins
  • Cilastatin
  • Imipenem
  • Cefoperazone
  • Cilastatin, Imipenem Drug Combination
  • Mezlocillin
Topics
  • Adult
  • Agranulocytosis (complications)
  • Anti-Bacterial Agents (adverse effects, therapeutic use)
  • Bacterial Infections (complications, drug therapy)
  • Cefoperazone (administration & dosage, adverse effects)
  • Cilastatin
  • Cilastatin, Imipenem Drug Combination
  • Cyclopropanes (adverse effects, therapeutic use)
  • Drug Combinations (adverse effects, therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Fever (complications)
  • Humans
  • Imipenem
  • Male
  • Mezlocillin (administration & dosage, adverse effects)
  • Neoplasms (complications)
  • Neutropenia (complications)
  • Thienamycins (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: